CN109745868A - 一种用于治疗尿毒症的抗菌中空纤维膜的制备方法 - Google Patents
一种用于治疗尿毒症的抗菌中空纤维膜的制备方法 Download PDFInfo
- Publication number
- CN109745868A CN109745868A CN201910071276.1A CN201910071276A CN109745868A CN 109745868 A CN109745868 A CN 109745868A CN 201910071276 A CN201910071276 A CN 201910071276A CN 109745868 A CN109745868 A CN 109745868A
- Authority
- CN
- China
- Prior art keywords
- fibre membrane
- polyether sulfone
- preparation
- hollow
- antibacterial hollow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 102
- 239000000835 fiber Substances 0.000 title claims abstract description 101
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 84
- 238000002360 preparation method Methods 0.000 title claims abstract description 57
- 239000004695 Polyether sulfone Substances 0.000 claims abstract description 118
- 229920006393 polyether sulfone Polymers 0.000 claims abstract description 118
- 238000005266 casting Methods 0.000 claims abstract description 69
- 229910052710 silicon Inorganic materials 0.000 claims abstract description 51
- 239000010703 silicon Substances 0.000 claims abstract description 51
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 6
- 230000004048 modification Effects 0.000 claims abstract description 4
- 238000012986 modification Methods 0.000 claims abstract description 4
- 238000002166 wet spinning Methods 0.000 claims abstract description 4
- 239000004332 silver Substances 0.000 claims abstract description 3
- 229910052709 silver Inorganic materials 0.000 claims abstract description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 266
- 239000000243 solution Substances 0.000 claims description 75
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 66
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 48
- 238000004176 ammonification Methods 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 29
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 29
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 29
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 29
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 29
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical group CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 28
- 229940113088 dimethylacetamide Drugs 0.000 claims description 28
- 239000000725 suspension Substances 0.000 claims description 25
- 238000002156 mixing Methods 0.000 claims description 24
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 24
- 230000001112 coagulating effect Effects 0.000 claims description 16
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 238000012545 processing Methods 0.000 claims description 13
- 238000009987 spinning Methods 0.000 claims description 13
- 238000006277 sulfonation reaction Methods 0.000 claims description 12
- 239000004088 foaming agent Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 239000012266 salt solution Substances 0.000 claims description 5
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- 150000008282 halocarbons Chemical class 0.000 claims description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 235000019441 ethanol Nutrition 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 238000007711 solidification Methods 0.000 claims description 2
- 230000008023 solidification Effects 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000005864 Sulphur Substances 0.000 claims 1
- 150000004040 pyrrolidinones Chemical class 0.000 claims 1
- 238000009938 salting Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 19
- 210000004369 blood Anatomy 0.000 abstract description 19
- 239000002441 uremic toxin Substances 0.000 abstract description 15
- 238000001631 haemodialysis Methods 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 7
- 239000003053 toxin Substances 0.000 abstract description 6
- 231100000765 toxin Toxicity 0.000 abstract description 6
- 108700012359 toxins Proteins 0.000 abstract description 6
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 abstract description 4
- 235000012489 doughnuts Nutrition 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 43
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 239000012153 distilled water Substances 0.000 description 21
- 238000011010 flushing procedure Methods 0.000 description 21
- 238000002791 soaking Methods 0.000 description 14
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 13
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 238000005406 washing Methods 0.000 description 13
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 11
- 208000037157 Azotemia Diseases 0.000 description 11
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 238000004090 dissolution Methods 0.000 description 11
- 230000010355 oscillation Effects 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 208000009852 uremia Diseases 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 150000001718 carbodiimides Chemical class 0.000 description 8
- -1 chloro propyl Chemical group 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 229930003779 Vitamin B12 Natural products 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 7
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 7
- 239000011715 vitamin B12 Substances 0.000 description 7
- 235000019163 vitamin B12 Nutrition 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 230000008081 blood perfusion Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940109239 creatinine Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000322 hemodialysis Effects 0.000 description 4
- 229940045136 urea Drugs 0.000 description 4
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000008237 rinsing water Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical class CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000003916 ethylene diamine group Chemical group 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- UQSQSQZYBQSBJZ-UHFFFAOYSA-N fluorosulfonic acid Chemical compound OS(F)(=O)=O UQSQSQZYBQSBJZ-UHFFFAOYSA-N 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Landscapes
- Artificial Filaments (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Description
尿素(%) | 肌酐(%) | 维生素B12(%) | 硫酸对甲酚(%) | |
实施例1 | 92.3 | 83.2 | 43.1 | 70.3 |
实施例2 | 91.9 | 84.1 | 42.5 | 74.0 |
实施例3 | 93.1 | 88.2 | 40.5 | 74.9 |
实施例4 | 92.5 | 86.2 | 40.4 | 79.4 |
实施例5 | 91.0 | 81.4 | 41.6 | 81.4 |
实施例6 | 92.0 | 81.4 | 42.8 | 76.3 |
实施例7 | 92.5 | 84.1 | 42.5 | 75.2 |
实施例8 | 91.7 | 84.2 | 41.5 | 72.4 |
实施例9 | 90.5 | 85.0 | 40.8 | 77.4 |
对比例1 | 86.7 | 77.9 | 38.9 | 30.7 |
对比例2 | 87.9 | 81.6 | 40.7 | 50.1 |
对比例3 | 73.1 | 67.6 | 38.6 | 42.9 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910071276.1A CN109745868B (zh) | 2019-01-25 | 2019-01-25 | 一种用于治疗尿毒症的抗菌中空纤维膜的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910071276.1A CN109745868B (zh) | 2019-01-25 | 2019-01-25 | 一种用于治疗尿毒症的抗菌中空纤维膜的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109745868A true CN109745868A (zh) | 2019-05-14 |
CN109745868B CN109745868B (zh) | 2021-05-25 |
Family
ID=66406202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910071276.1A Active CN109745868B (zh) | 2019-01-25 | 2019-01-25 | 一种用于治疗尿毒症的抗菌中空纤维膜的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109745868B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020151228A1 (zh) * | 2019-01-25 | 2020-07-30 | 广东省医疗器械研究所 | 一种用于血液净化的抗菌中空纤维膜的制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103285740A (zh) * | 2012-02-23 | 2013-09-11 | 中国科学院宁波材料技术与工程研究所 | 一种抗菌双层中空纤维膜的制备方法 |
US20130233791A1 (en) * | 2012-03-08 | 2013-09-12 | Korea Institute Of Science And Technology | Separation membrane for water treatment and manufacturing method thereof |
CN103394334B (zh) * | 2013-07-11 | 2015-07-08 | 东华大学 | 一种高比表面积胺化纳米纤维膜的制备方法 |
CN105617876A (zh) * | 2014-11-06 | 2016-06-01 | 中国科学院宁波材料技术与工程研究所 | 一种缓释型抗菌双层中空纤维膜及其制备方法 |
CN106232213A (zh) * | 2014-05-01 | 2016-12-14 | 沙特基础工业全球技术有限公司 | 具有包含聚(亚苯基醚)和两亲聚合物的支持物的复合膜、制造方法及其分离组件 |
CN106582304A (zh) * | 2016-12-30 | 2017-04-26 | 浙江工业大学 | 一种荷电镶嵌膜的制备方法 |
CN107955171A (zh) * | 2017-12-26 | 2018-04-24 | 珠海健帆生物科技股份有限公司 | 一种蛋白结合毒素印迹硅胶吸附剂的制备方法及吸附装置 |
-
2019
- 2019-01-25 CN CN201910071276.1A patent/CN109745868B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103285740A (zh) * | 2012-02-23 | 2013-09-11 | 中国科学院宁波材料技术与工程研究所 | 一种抗菌双层中空纤维膜的制备方法 |
US20130233791A1 (en) * | 2012-03-08 | 2013-09-12 | Korea Institute Of Science And Technology | Separation membrane for water treatment and manufacturing method thereof |
CN103394334B (zh) * | 2013-07-11 | 2015-07-08 | 东华大学 | 一种高比表面积胺化纳米纤维膜的制备方法 |
CN106232213A (zh) * | 2014-05-01 | 2016-12-14 | 沙特基础工业全球技术有限公司 | 具有包含聚(亚苯基醚)和两亲聚合物的支持物的复合膜、制造方法及其分离组件 |
CN105617876A (zh) * | 2014-11-06 | 2016-06-01 | 中国科学院宁波材料技术与工程研究所 | 一种缓释型抗菌双层中空纤维膜及其制备方法 |
CN106582304A (zh) * | 2016-12-30 | 2017-04-26 | 浙江工业大学 | 一种荷电镶嵌膜的制备方法 |
CN107955171A (zh) * | 2017-12-26 | 2018-04-24 | 珠海健帆生物科技股份有限公司 | 一种蛋白结合毒素印迹硅胶吸附剂的制备方法及吸附装置 |
Non-Patent Citations (4)
Title |
---|
侯长军: "聚醚砜(PES)改性血液相容性材料的制备及相关生物学特性研究", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
吴范宏等: "《应用化学》", 31 August 2016, 华东理工大学出版社 * |
王湛: "《膜分离技术基础》", 30 April 2000, 化学工业出版社 * |
赵显国等: "《尿毒症诊疗学》", 31 January 1998, 河南医科大学出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020151228A1 (zh) * | 2019-01-25 | 2020-07-30 | 广东省医疗器械研究所 | 一种用于血液净化的抗菌中空纤维膜的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN109745868B (zh) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018278913B2 (en) | Hemodialyzer for blood purification | |
Idris et al. | The effect of different molecular weight PEG additives on cellulose acetate asymmetric dialysis membrane performance | |
CN101703893A (zh) | 空心纤维超滤复合膜及其制备方法和应用 | |
CN103301759B (zh) | 一种聚砜空心纤维透析膜及其制造方法 | |
JPH0647262A (ja) | 全血からの低密度リポタンパク質の高効率除去 | |
EP1572330A1 (en) | Perm selective asymmetric hollow fibre membrane for the separation of toxic mediators from blood | |
WO2009040123A1 (en) | Hydrophilic membranes with a non-ionic surfactant | |
CN105709613B (zh) | 一种有效去除中等生物分子的纳米纤维复合膜及其制备方法和应用 | |
CN106310970B (zh) | 一种用于血液透析的改性聚偏氟乙烯中空纤维膜 | |
Su et al. | Polyethersulfone hollow fiber membranes for hemodialysis | |
Ismail et al. | Hemodialysis membrane for blood purification process | |
CN109745868A (zh) | 一种用于治疗尿毒症的抗菌中空纤维膜的制备方法 | |
US9950103B2 (en) | Combination kidney and liver dialysis system and method | |
CN109794172B (zh) | 一种用于血液净化的抗菌中空纤维膜的制备方法 | |
CN116966756A (zh) | 一种清除促炎性细胞因子的血液净化膜及其制备方法 | |
EP4061519A1 (en) | Porous membranes comprising sorbent particles for improved urea capture | |
CN109758930B (zh) | 一种治疗高血脂症用的中空纤维膜的制备方法 | |
CN107381970B (zh) | 一种透析废液净化装置 | |
EP3609608A1 (en) | Extracorporeal blood circuit | |
Raharjo et al. | Selectively mixed matrix hemodialysis membrane for adequate clearance of p-cresol by the incorporation of imprinted zeolite | |
CN114392655A (zh) | 一种血液透析滤过膜的制备方法 | |
CN103252177A (zh) | 一种糖基/磺化改性亲和聚合物中空纤维分离膜、其制备方法及用途 | |
JP2011000145A (ja) | 中空糸状血液浄化膜及び中空糸状血液浄化膜の製造方法 | |
CN207537303U (zh) | 一种透析废液净化装置 | |
JP4003982B2 (ja) | ポリスルホン系選択透過性分離膜 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 1307, Guangzhou Avenue middle, Tianhe District, Guangzhou, Guangdong 510500 Patentee after: Institute of health medicine, Guangdong Academy of Sciences Country or region after: China Address before: No. 1307, Guangzhou Avenue middle, Tianhe District, Guangzhou, Guangdong 510500 Patentee before: GUANGDONG INSTITUTE OF MEDICAL INSTRUMENTS Country or region before: China |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240206 Address after: No.10, shiliugang Road, Haizhu District, Guangzhou City, Guangdong Province 510000 Patentee after: Institute of biological and medical engineering, Guangdong Academy of Sciences Country or region after: China Address before: No. 1307, Guangzhou Avenue middle, Tianhe District, Guangzhou, Guangdong 510500 Patentee before: Institute of health medicine, Guangdong Academy of Sciences Country or region before: China |